drugset / Trial / NCT00471159

A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.

NCT00471159

Phase 2 Withdrawn Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

To assess the efficacy and safety of PF-3512676 administered in combination with docetaxel for the treatment of patients with advanced breast cancer.

Timeline

Start
2007-08
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject agatolimod Oligonucleotide (other)
Background Docetaxel Small molecule

Indications